You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK)與BOOSTIMMUNE訂立抗體偶聯藥物發現合作協議
格隆匯 02-27 08:13

格隆匯2月27日丨和鉑醫藥-B(02142.HK)發佈公吿,公司全資子公司諾納生物(蘇州)有限公司(“諾納生物”)已與Boostimmune, Inc.(“Boostimmune”)訂立抗體偶聯藥物(“ADC”)發現合作協議,以為公司開發ADC療法建立戰略伙伴關係。根據協議,諾納生物將為Boostimmune提供其雙重、雙輕鏈(H2L2) Harbour Mice®平台,以開發針對新型靶點的ADC療法。

隨着諾納生物以全球戰略視角擴展集團的合作網絡,此次合作成為集團的一個里程碑,亦標誌行業對集團專有平台及抗體發現能力的認可。公司相信, Harbour Mice®平台連同集團在創新生物藥物發現方面積累的豐富經驗可產生差異化治療分子,使全球患者受益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account